Success Metrics

Clinical Success Rate

100.0%

Based on 5 completed trials

Completion Rate

100%(5/5)

Active Trials

0(0%)

Results Posted

80%(4 trials)

Phase Distribution

Ph early_phase_1

33%

Ph not_applicable

17%

Ph phase_2

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Early Phase 1First-in-human

2(33.3%)

Phase 2Efficacy & side effects

3(50.0%)

N/ANon-phased studies

1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Terminated(1)

Detailed Status

Completed5

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Early Phase 12 (33.3%)

Phase 23 (50.0%)

N/A1 (16.7%)

Trials by Status

withdrawn117%

completed583%

Recent Activity

0 active trials

Showing 5 of 6

completedphase_2

Anti-1-amino-3-[18F]Fluorocyclobutyl-1-carboxylic Acid (Anti-[18F](FACBC)Positron Emission Tomography (PET-CT) of the Breast

NCT01659645

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT01666808Phase 2

FACBC Outcomes for Post Prostatectomy

Completed

NCT01574287Not Applicable

Anti-3-[18F]FACBC Imaging of Parathyroid Adenomas

Completed

NCT01808222Phase 2

FACBC for Recurrent Prostate Cancer

Completed

NCT01933269Early Phase 1

FACBC for Head and Neck Cancers

Withdrawn

NCT01659645Early Phase 1

Anti-1-amino-3-[18F]Fluorocyclobutyl-1-carboxylic Acid (Anti-[18F](FACBC)Positron Emission Tomography (PET-CT) of the Breast

Completed

NCT00562315Phase 2

FACBC PET/CT for Recurrent Prostate Cancer

Completed

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6